TB-500 is a synthetic peptide corresponding to a specific active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found across mammalian cell types. Some TB-500 products on the research market represent the full Tβ4 sequence, while others are the shorter active fragment (Ac-LKKTETQ) corresponding to amino acids 17-23 of the parent protein.
Thymosin Beta-4 was first isolated from calf thymus tissue and has since been identified as one of the most abundant intracellular proteins in mammalian cells, with notable conservation across species.
Primary Mechanism: Actin Regulation
The best-characterised mechanism associated with this peptide is its role as a G-actin sequestering protein. It binds monomeric (globular) actin with high affinity in a 1:1 stoichiometric interaction, preventing premature polymerisation into filamentous actin. By maintaining a reservoir of unpolymerised actin within the cell, the peptide appears to enable rapid cytoskeletal remodelling in response to cellular signalling.
Documented Research Areas
Angiogenesis
Research has reported that thymosin beta-4 and TB-500 promote angiogenesis through upregulation of vascular endothelial growth factor (VEGF) expression and enhanced endothelial cell migration. Some studies have quantified VEGF mRNA expression increases in the range of 2.5 to 3.8-fold across various cell types following treatment.
Cell Migration and Tissue Remodelling
A substantial portion of the literature on this compound focuses on cell migration — the process by which cells move toward sites of injury or remodelling. Because actin polymerisation underlies the physical mechanics of cell movement, the peptide’s actin-sequestering activity is mechanistically linked to enhanced migratory capacity observed in treated cell populations.
Cardiovascular Research
A meaningful subset of the preclinical literature has examined thymosin beta-4 in cardiac injury models, with some studies reporting reduced infarct size and improved cardiac function measures following induced myocardial injury in animal models.
Other Investigated Pathways
Research has also explored the peptide’s relationship to inflammatory signalling and immune cell trafficking to sites of tissue injury, alongside preliminary work on bone remodelling and neurological recovery models.
What the Research Does Not Establish
Most of the human-relevant data available comes from clinical trials of the full thymosin beta-4 molecule under names such as RGN-259 (studied for dry eye) and RGN-137 (studied for chronic wounds) — not from TB-500 specifically. These trial compounds share the same active region as TB-500 but are not interchangeable with TB-500 as sold on the research market.
The bulk of TB-500-specific evidence is preclinical. As with many research peptides, this is precisely why independent, batch-specific testing matters for any research use of this compound.
Sourcing Research-Grade TB-500
Any TB-500 used in a laboratory setting should be accompanied by a batch-specific Certificate of Analysis confirming identity, HPLC purity, and screening for heavy metals and endotoxins. At Claripep, every batch is independently tested by a third-party laboratory before listing. For researchers also working with BPC-157, see our comparison of the two compounds’ distinct mechanisms.
This article is provided for research and educational purposes only. It does not constitute medical advice and should not be interpreted as promoting human or veterinary use of this compound. All products supplied by Claripep Ltd are intended strictly for laboratory research applications.